Frontier Biotechnologies Gets Nod to Trial Kidney Disease Drug

MT Newswires Live01-02

Frontier Biotechnologies (SHA:688221) has obtained approval from China's National Medical Products Administration to carry out a clinical trial of its FB7013 injection, according to a Thursday filing with the Shanghai Stock Exchange.

FB7013 is a siRNA drug indicated to reduce kidney tissue damage for patients with immunoglobulin A nephropathy (IgA nephropathy).

The company said it can be expanded to multiple areas of diseases related to membranous nephropathy and diabetic nephropathy.

Citing data from Frost & Sullivan, Frontier said the number of patients with IgA globally increased to 9.3 million in 2020 from 8.8 million in 2015, and is forecast to reach 10.2 million by 2030.

The global market for nephropathy treatments is estimated to have reached $1.2 billion in 2025 from $567 million in 2020, representing a 16.1% CAGR, Frontier added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2600703797?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-02 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2600703797","market":"hk","top_or_hot":-1,"title":"Frontier Biotechnologies Gets Nod to Trial Kidney Disease Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/688221\">Frontier Biotechnologies</a> (SHA:688221) has obtained approval from China's National Medical Products Administration to carry out a clinical trial of its FB7013 injection, according to a Thursday filing with the Shanghai Stock Exchange.</p><p>FB7013 is a siRNA drug indicated to reduce kidney tissue damage for patients with immunoglobulin A nephropathy (IgA nephropathy).</p><p>The company said it can be expanded to multiple areas of diseases related to membranous nephropathy and diabetic nephropathy.</p><p>Citing data from Frost &amp; Sullivan, Frontier said the number of patients with IgA globally increased to 9.3 million in 2020 from 8.8 million in 2015, and is forecast to reach 10.2 million by 2030.</p><p>The global market for nephropathy treatments is estimated to have reached $1.2 billion in 2025 from $567 million in 2020, representing a 16.1% CAGR, Frontier added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Frontier Biotechnologies Gets Nod to Trial Kidney Disease Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFrontier Biotechnologies Gets Nod to Trial Kidney Disease Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-02 09:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/688221\">Frontier Biotechnologies</a> (SHA:688221) has obtained approval from China's National Medical Products Administration to carry out a clinical trial of its FB7013 injection, according to a Thursday filing with the Shanghai Stock Exchange.</p><p>FB7013 is a siRNA drug indicated to reduce kidney tissue damage for patients with immunoglobulin A nephropathy (IgA nephropathy).</p><p>The company said it can be expanded to multiple areas of diseases related to membranous nephropathy and diabetic nephropathy.</p><p>Citing data from Frost &amp; Sullivan, Frontier said the number of patients with IgA globally increased to 9.3 million in 2020 from 8.8 million in 2015, and is forecast to reach 10.2 million by 2030.</p><p>The global market for nephropathy treatments is estimated to have reached $1.2 billion in 2025 from $567 million in 2020, representing a 16.1% CAGR, Frontier added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2600703797","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2600703797","pubTimestamp":1767317521,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Frontier Biotechnologies  has obtained approval from China's National Medical Products Administration to carry out a clinical trial of its FB7013 injection, according to a Thursday filing with the Shanghai Stock Exchange.FB7013 is a siRNA drug indicated to reduce kidney tissue damage for patients with immunoglobulin A nephropathy .The company said it can be expanded to multiple areas of diseases related to membranous nephropathy and diabetic nephropathy.Citing data from Frost & Sullivan, Frontier said the number of patients with IgA globally increased to 9.3 million in 2020 from 8.8 million in 2015, and is forecast to reach 10.2 million by 2030.The global market for nephropathy treatments is estimated to have reached $1.2 billion in 2025 from $567 million in 2020, representing a 16.1% CAGR, Frontier added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688221":"前沿生物","BK0239":"医药制造","FTR":"Frontier通信B系列"},"translate_title":"Frontier Biotechnologies获得肾病药物试验许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688221":0.9,"FTR":1.5},"content_text":"Frontier Biotechnologies (SHA:688221) has obtained approval from China's National Medical Products Administration to carry out a clinical trial of its FB7013 injection, according to a Thursday filing with the Shanghai Stock Exchange.FB7013 is a siRNA drug indicated to reduce kidney tissue damage for patients with immunoglobulin A nephropathy (IgA nephropathy).The company said it can be expanded to multiple areas of diseases related to membranous nephropathy and diabetic nephropathy.Citing data from Frost & Sullivan, Frontier said the number of patients with IgA globally increased to 9.3 million in 2020 from 8.8 million in 2015, and is forecast to reach 10.2 million by 2030.The global market for nephropathy treatments is estimated to have reached $1.2 billion in 2025 from $567 million in 2020, representing a 16.1% CAGR, Frontier added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2600703797","isCrawlerRequest":true}